恒瑞医药(01276.HK)：“HRS-4642注射液”被药审中心纳入突破性治疗品种名单

Group 1 - Core viewpoint: Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration [1] - Drug name: HRS-4642 injection, application number: CXHL2400083, classified as a Class 1 chemical drug [2] - Proposed indication: To be used in combination with gemcitabine and albumin-bound paclitaxel for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation [2] Group 2 - Application date for HRS-4642: December 24, 2025 [2] - The application meets the requirements of the Drug Registration Management Measures and the announcement regarding the breakthrough therapeutic drug review procedures [2]